LOS ANGELES (KABC) -- Many people taking a popular diabetes medication have been experiencing weight loss as one of the side effects. Low blood sugar levels brought 59-year-old Anda Lam to her ...

Danish Novo Nordisk, the world's biggest insulin producer, said on Friday it had received a product label update for diabetes drug Victoza to include data showing superior efficacy when compared with ...

Novo Nordisk launched a consumer campaign for Victoza, emphasizing the product’s ability to bring down blood sugar levels and body weight in patients with type 2 diabetes. The campaign features print ...

Branded content furnished by our promotional partners. The Daily Sundial editorial staff is not involved in its production. Content does not reflect the views or opinions of the editorial staff.

Novo Nordisk's Victoza, a popular diabetes medication, has shown mixed results in a mid-stage trial targeting Alzheimer's disease. While the drug failed to meet its primary endpoint of improving brain ...

A woman who’s been on a drug similar to Ozempic for nearly a decade is sharing what she’s learned. Danielle Payton, 33, is believed to be one of the longest-serving patients on a GLP-1 injection. The ...

Novo Nordisk's (NVO) new type-2 diabetes drug Victoza is rapidly gaining market share in the all-important U.S. market. The Danish drug maker's early commercial success with its subcutaneous "GLP-1" ...

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023. The Danish pharma ...

Mylan, coming off a big patent win against Biogen, aims to launch a copycat version of Novo Nordisk's diabetes drug Victoza. Now, a U.S. patent office panel says there's a "reasonable likelihood" that ...

Indication(s): As adjunct to diet and exercise, to improve glycemic control in type 2 diabetes. The approval of Victoza in this patient population was based on data from the ELLIPSE trial which ...

Two products for the treatment of type 2 diabetes, insulin degludec (Tresiba) and liraglutide (Victoza), both from Danish drug firm Novo Nordisk, have this week been given positive opinions for ...